Leveraged patient-level data (APLD) and NSP data to capture raw market size and share, providing a foundation for accurate market trend projections.
Developed a relevant mBC patient universe with tailored business rules for BC/HR+/HER2- populations, ensuring accurate insights and market representation.
Analyzed market size, share, and LOT performance, treatment duration (DOT) by regimen, and source of business (SOB), providing deeper insights into therapy adoption and competitive dynamics.
Delivered comprehensive payer-mix and competitive landscape analysis, aligning client strategies with the latest market trends.
Developed a dynamic mBC Market Dashboard, enabling real-time visibility for faster decision-making.
Empowered the client with precise go-to-market planning and patient adoption forecasting.
Refined commercial strategies, enhancing competitive advantage in the oncology market.